Gilead Sciences (GILD) Payables (2009 - 2026)

Gilead Sciences (GILD) has reported Payables for 18 consecutive years, with $674.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 15.81% year-over-year to $674.0 million; the trailing twelve-month figure through Jun 2026 stood at $674.0 million (up 15.81% YoY), and the FY2025 full-year result was $715.0 million, down 14.17% from the prior year.
• Payables improved to $674.0 million in Q2 2026 per GILD's latest filing, from $645.0 million in the prior quarter.
• Across five years, Payables topped out at $905.0 million in Q4 2022 and bottomed at $537.0 million in Q2 2024.
• Historically, Payables has averaged $672.7 million across 5 years, with a median of $624.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Payables plunged 39.23% in 2023, then surged 54.1% in 2024.
• Over 5 years, Payables stood at $905.0 million in 2022, then slumped by 39.23% to $550.0 million in 2023, then jumped by 51.45% to $833.0 million in 2024, then dropped by 14.17% to $715.0 million in 2025, then decreased by 5.73% to $674.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $674.0 million, $645.0 million, and $715.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.